Prognostic implications of the ID1 expression in acute myeloid leukemia patients treated in a resource-constrained setting.

ABSTRACT:

Introduction

The aberrant expression of the inhibitor of DNA binding (ID1) gene has been frequently associated with the leukemogenesis and prognostication acute myeloid leukemia (AML), although its clinical importance has never been investigated in patients treated outside well-controlled clinical trials.

Methods

Using quantitative real-time polymerase chain reaction, we investigated the role of the ID1 expression in the clinical outcomes of non-selected patients with acute myeloid leukemia treated in a real-life setting.

Results

Overall, 128 patients were enrolled. Patients with high ID1 expression had a lower 3-year overall survival (OS) rate of 9%, with the 95% confidence interval (95%CI) at 3 to 20%, compared to patients with a low ID1 expression (22%, 95%CI: 11 -

SUBMITTER: Lima AS 

PROVIDER: S-EPMC11221249 | biostudies-literature | 2024 Jul-Sep

REPOSITORIES: biostudies-literature